Protocol Ledger

NCT04988035 · Phase II · COMPLETED

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

Interventional Phase II clinical trial protocol NCT04988035 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-03 Enrollment: 201 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04988035
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)201 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04988035
Protocol FieldVerified Registry Value
NCT IdentifierNCT04988035
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment201 participants (ACTUAL)
Registered Start Date2021-08-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04988035
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI